Alnylam Pharma Stock Could Be Worth $200 In 3 Years

Alnylam Pharmaceuticals has seen its stock rise by 17% this year. The stock now trades at over 33x projected 2020 revenues, despite the fact that the company is likely to post another loss this year. Does this make the stock expensive? Probably not.

About the Author

has written 23527 stories on this site.

Copyright © 2010 corporatecommunicationsnews101.com